based Regimens in Chinese Patients With Multiple Myeloma

treatment response, survival outcomes, and safety in Chinese patients with MM who were treated with DARA-based regimens in routine clinical practice. Methods.

Bortezomib-Based Regimens for Newly Diagnosed Multiple ...

Bortezomib-Based Regimens for Newly Diagnosed Multiple Myeloma in China: A ... Front Pharmacol. 2020 Dec 11:11:561601. doi: 10.3389/fphar.2020.561601.

Real-World Analysis of Treatment Patterns and the Effectiveness ...

... Based Regimens in Chinese Patients with Newly Diagnosed or Relapsed/Refractory Multiple Myeloma. Author links open overlay panel. Luqun Wang 1 , Wei Yang MD 2 ,

Bortezomib-Based Regimens for Newly Diagnosed Multiple ...

In 2006, bortezomib was approved for the treatment of MM patients in China, and has been adopted as the first-line treatment option for MM since ...

Long-term outcomes of different bortezomib-based regimens in ...

Abstract: Bortezomib has significantly increased the response rates in multiple myeloma (MM), but optimal bortezomib-based regimens for initial ...

long-term outcomes of different bortezomib- based regimens in ...

bortezomib-based regimens in Chinese myeloma patients. ... patients with multiple myeloma treated with high-dose therapy: long- ... multiple myeloma patients ...

(PDF) Bortezomib-Based Regimens for Newly Diagnosed Multiple ...

Background: Improve the treatment quality might affect patients' efficacy and survival. Methods: Five hundred thirty multiple myeloma ...

The evolving diagnosis and treatment paradigms of multiple ...

Significant advances in multiple myeloma (MM) over the past 15 years led to exciting changes in the management of MM patients in China, which in ...

Phase 1 study of isatuximab monotherapy in Chinese patients with ...

... myeloma activity in Chinese patients with relapsed/refractory multiple myeloma (RRMM) ... therapy regimens for patients with multiple myeloma. Adv.

PP455 Cost-effectiveness Of Ixazomib-Based Regimen Compared ...

The treatment of relapsed/refractory multiple myeloma (RRMM), a common hematological malignancy, remains a great challenge in China, partially ...

Current status of drug development for patients with multiple myeloma

The combination of daratumumab, bortezomib and dexamethasone achieved favorable outcomes as the first-line therapy in China. However, high-risk patients have ...

Treatment Patterns and Outcomes in Patients with Multiple Myeloma ...

Novel drugs such as PIs, immunomodulatory drugs (IMDs), and anti-CD-38 monoclonal antibodies are the core component of MM treatment and have ...

Clinical outcomes of pomalidomide‐based and daratumumab ...

Clinical outcomes of pomalidomide-based and daratumumab-based therapies in patients with relapsed/refractory multiple myeloma: A real-world ...

Daratumumab, Bortezomib, and Dexamethasone Versus ...

Original Study. Daratumumab, Bortezomib, and Dexamethasone Versus Bortezomib and Dexamethasone in Chinese Patients with Relapsed or Refractory Multiple Myeloma: ...

Current treatment paradigm and survival outcomes among patients ...

Conclusions: Our study showed that novel agent-based regimens, first-line ASCT, and sustained MRD negativity were associated with a superior ...

The Choice of Regimens Based on Bortezomib for Patients ... - PLOS

Bortezomib has significantly improved multiple myeloma (MM) response rates, but strategies for choosing bortezomib-based regimens for initial MM therapy are not ...

Long-term outcomes of different bortezomib-based regimens in ...

... multiple myeloma (MM), but optimal bortezomib-based regimens for initial MM therapy ... patients with multiple myeloma treated with high-dose therapy: long-. term ...

Selinexor plus low-dose dexamethasone in Chinese patients with ...

The MARCH study was conducted at 17 sites in China, where eligible Chinese RRMM patients who had disease refractory to PI and IMiD were enrolled ...

Treatment attrition rates and relevant risk factors in multiple myeloma

A significant change in the treatment pattern of MM patients occurred around 2017, after which Bortezomib-based regimens became the main protocol. Although ...

Chinese consensus recommendations for the clinical application of ...

Many studies have confirmed that the combination regimens based on selinexor in the treatment of relapsed and refractory multiple myeloma have achieved a high ...